Sabarubicin (SABA) in combination with cisplatin (DDP): Maximum tolerated dose (MTD) evaluation (phase I step) followed by a phase II step in patients (pts) with small cell lung cancer-extensive disease (SCLC-ED)

Autor:	J. Wolf, A. Capriati, Meinolf Karthaus, C. Simonelli, M. Sebastian, T. Mueller, Oliver A. Cornely, K. M. Josten, W. Neumeister, H. A. Duerk
Rok vydání:	2010
Předmět:	Oncology Cisplatin Cancer Research medicine.medical_specialty endocrine system diseases Extensive Disease Anthracycline business.industry Surgery Internal medicine Maximum tolerated dose Medicine Single agent In patient Non small cell business Sabarubicin medicine.drug
Zdroj:	Journal of Clinical Oncology. 28:7048-7048
ISSN:	1527-7755 0732-183X
Popis:	7048 Background: SABA, a 3rd generation anthracycline with promising activity as single agent in solid tumors was evaluated to establish the MTD in combination with DDP (phase I), followed by a pha...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ac4c3752b1198dd1517f24f7cf9dea49 https://doi.org/10.1200/jco.2010.28.15_suppl.7048 Zobrazit plný text záznamu